Literature DB >> 15838870

Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis.

Frank Gillardon1, André Schrattenholz, Bernd Sommer.   

Abstract

Small molecule inhibitors of cyclin-dependent kinase 5 (CDK5) protect neurons from cell death following various insults. To elucidate the cellular mechanism of action we investigated changes in protein phosphorylation in cultured rat cerebellar granule neurons after administration of the CDK5 inhibitor Indolinone A. By immunoblot analysis we detected enhanced phosphorylation of the extracellular signal-regulated kinase1/2 (ERK1/2) and the Jun N-terminal kinase (JNK) substrate c-Jun. Co-administration of U0126, an inhibitor of ERK1/2, or SP600125, an inhibitor of JNK, blocked phosphorylation of ERK1/2 or c-Jun, but did not affect neuroprotection by the CDK5 inhibitor. By metal affinity chromatography, two-dimensional (2D) gel electrophoresis, and MALDI-TOF mass spectrometry we identified several phosphoproteins that accumulated in neurons treated with Indolinone A. Among them were proteins involved in neurotransmitter release, which is consistent with a physiological function of CDK5 in synaptic signaling. Moreover, we identified proteins acting in energy metabolism, protein folding, and oxidative stress response. Similar findings have been reported in yeast following inhibition of Pho85 kinase, which is homologous to mammalian CDK5 and acts in environmental stress signaling. These results suggest that inhibition of CDK5 activates stress responsive proteins that may protect neurons against subsequent injurious stimuli.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15838870     DOI: 10.1002/jcb.20463

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Ischemic stroke injury is mediated by aberrant Cdk5.

Authors:  Douglas A Meyer; Melissa I Torres-Altoro; Zhenjun Tan; Alessandro Tozzi; Massimiliano Di Filippo; Vincent DiNapoli; Florian Plattner; Janice W Kansy; Stanley A Benkovic; Jason D Huber; Diane B Miller; Paul Greengard; Paolo Calabresi; Charles L Rosen; James A Bibb
Journal:  J Neurosci       Date:  2014-06-11       Impact factor: 6.167

2.  Regulation of protein phosphatase inhibitor-1 by cyclin-dependent kinase 5.

Authors:  Chan Nguyen; Akinori Nishi; Janice W Kansy; Joseph Fernandez; Kanehiro Hayashi; Frank Gillardon; Hugh C Hemmings; Angus C Nairn; James A Bibb
Journal:  J Biol Chem       Date:  2007-03-30       Impact factor: 5.157

Review 3.  Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.

Authors:  Gerald Schmid; Joanna B Strosznajder; Józefa Wesierska-Gadek
Journal:  Mol Neurobiol       Date:  2006-08       Impact factor: 5.590

Review 4.  Neuroprotective Mechanisms Mediated by CDK5 Inhibition.

Authors:  Gohar Mushtaq; Nigel H Greig; Firoz Anwar; Fahad A Al-Abbasi; Mazin A Zamzami; Hasan A Al-Talhi; Mohammad A Kamal
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

5.  Soluble alpha-APP (sAPPalpha) regulates CDK5 expression and activity in neurons.

Authors:  Daniela Hartl; Stephan Klatt; Manfred Roch; Zoltan Konthur; Joachim Klose; Thomas E Willnow; Michael Rohe
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

6.  Searching for novel Cdk5 substrates in brain by comparative phosphoproteomics of wild type and Cdk5-/- mice.

Authors:  Erick Contreras-Vallejos; Elías Utreras; Daniel A Bórquez; Michaela Prochazkova; Anita Terse; Howard Jaffe; Andrea Toledo; Cristina Arruti; Harish C Pant; Ashok B Kulkarni; Christian González-Billault
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.